AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$ROIV

Fitzgerald Meghan sold $203K of ROIV

Fitzgerald Meghan sold 5,112 shares of Roivant Sciences Ltd. (ROIV) at an average of $39.74 ($39.68–$40.45, $0.20M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fitzgerald Meghan
Published Sep 17, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Neutral
high confidence
Mentioned
$ROIV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect ROIV's valuation.

02

Market read

Minor insider transaction with limited trading relevance.

03

What to watch

Potential upcoming dilution or secondary offerings not disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

Form 4 filings disclose insider trades; investors monitor for material changes.

Company-level read

Ticker impact

$ROIVNeutralHigh confidence
Context

Director Meghan Fitzgerald sold 5,112 shares for $203,152 via a 10b5‑1 plan on 2026‑09‑15.

Expected impact

minimal to none

Evidence & confidence

Sale size is modest relative to float and disclosed as a routine 10b5‑1 transaction.

Market effects

Sector

None; isolated insider transaction.

Regional

None; limited to Roivant shareholders.

Global

None

Counterpoint

What could challenge this read

Insider sell could signal concerns, but size is too small to act on.

Key entities

  • Company
    Roivant Sciences Ltd.

    Biopharma company listed on Nasdaq under ROIV.

  • Insider
    Meghan Fitzgerald

    Director of Roivant Sciences who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 23
$ROIVHighAI 9/10

Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials

Roivant Sciences shares rose 8% after brepocitinib met primary and secondary endpoints in two Phase 3 trials for non-infectious uveitis. The drug, already approved for dermatomyositis, showed significant improvement over placebo. Roivant plans an FDA filing for the new indication in early 2027. The company has $3.84 billion in cash and a market cap of about $25 billion.

finance.yahoo.com2 min
OCT 21
$ROIVHighAI 9/10

Why is Roivant Sciences stock rallying today?

Roivant Sciences (ROIV) rose 6.8% after its drug brepocitinib met all primary and secondary endpoints in Phase 3 trials for non-infectious uveitis. The company plans to submit an FDA application in 2027. Citi analyst Samantha Semenkow has a $46 price target and Buy rating on ROIV, citing the trial results. The stock reached $37.30, near its 52-week high of $42.50.

investing.com2 min
OCT 21
$ROIVHighAI 9/10

Roivant Sciences stock surges on positive uveitis trial data

Roivant Sciences (NASDAQ:ROIV) shares rose 9% premarket after announcing brepocitinib met all Phase 3 trial endpoints for non-infectious uveitis. The drug showed significant benefit over placebo in both CLARITY-1 and CLARITY-2 trials. Priovant Therapeutics, a Roivant subsidiary, plans to file a supplemental New Drug Application in the first half of 2027.

investing.com2 min